Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 54

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 54
---
.87 per share, the last reported sale price of our common stock on the Nasdaq Global Market on August 11, 2025 and after deducting commissions and estimated aggregate offering expenses payable by us, our net tangible book value as of June 30, 2025 would have been $211.0 million, or $3.97 per share of common stock. This represents an immediate increase in the net tangible book value of $3.62 per share to our existing stockholders and an immediate dilution in net tangible book value of $61.90 per share to new investors. We determine dilution by subtracting our as adjusted net tangible book value per share after this offering from the amount of cash paid by an investor for a share of common stock in this offering. The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share                                                   |     |        |     | $ | 65.87 |
| Net tangible book value per share as of June 30, 2025                                     |     | $ 0.35 |     |   |       |
| Increase in net tangible book value per share attributable to this offering               |     | $ 3.62 |     |   |       |
| As adjusted net tangible book value per share as of June 30, 2025, after giving effect to 
 this offering                                                                             |     |        |     | $ |  3.97 |
| Dilution per share to new investors purchasing shares in this offering                    |     |        |     | $ | 61.90 |

The table above assumes for illustrative purposes that an aggregate of 3,036,283 shares of our common stock are sold under the sales agreement at a price of $65.87 per share, the last reported sale price of our common stock on the Nasdaq Global Market on August 11, 2025, for aggregate gross proceeds of $200.0 million. The shares subject to the sales agreement are being sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $65.87 per share, assuming all of our common stock in the aggregate amount of $200.0 million is sold at that price, would increase our as adjusted net tangible book value per share after the offering to $3.98 per share and would increase the dilution in net tangible book value per share to new investors in this